| 2.24 -0.05 (-2.18%) | 02-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.45 |
1-year : | 3.99 |
| Resists | First : | 2.95 |
Second : | 3.42 |
| Pivot price | 2.69 |
|||
| Supports | First : | 2.21 |
Second : | 1.83 |
| MAs | MA(5) : | 2.35 |
MA(20) : | 2.77 |
| MA(100) : | 2.68 |
MA(250) : | 3.04 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.8 |
D(3) : | 5.2 |
| RSI | RSI(14): 33.5 |
|||
| 52-week | High : | 6.3 | Low : | 1.87 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AKYA ] has closed above bottom band by 10.7%. Bollinger Bands are 42% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.29 - 2.31 | 2.31 - 2.32 |
| Low: | 2.17 - 2.19 | 2.19 - 2.21 |
| Close: | 2.21 - 2.24 | 2.24 - 2.27 |
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Wed, 12 Feb 2025
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook - br.ADVFN.com
Wed, 05 Feb 2025
Revolutionary Neurobiology Panels: Akoya's New Weapon Against Brain Disease Research - StockTitan
Wed, 05 Feb 2025
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Large Increase in Short Interest - MarketBeat
Tue, 28 Jan 2025
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner - Business Wire
Tue, 28 Jan 2025
Major Breakthrough: Akoya's Advanced Diagnostic Tech Gets Manufacturing Powerhouse Backing - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 50 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 11 (%) |
| Held by Institutions | 70.1 (%) |
| Shares Short | 1,600 (K) |
| Shares Short P.Month | 2,360 (K) |
| EPS | -1.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.1 |
| Profit Margin | -64.8 % |
| Operating Margin | -47.5 % |
| Return on Assets (ttm) | -18.1 % |
| Return on Equity (ttm) | -128.2 % |
| Qtrly Rev. Growth | -1.5 % |
| Gross Profit (p.s.) | 1.08 |
| Sales Per Share | 1.88 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -51 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -1.94 |
| PEG Ratio | 0 |
| Price to Book value | 2.03 |
| Price to Sales | 1.19 |
| Price to Cash Flow | -2.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|